

ASX ANNOUNCEMENT

MARKET RELEASE

02 April 2024

Artrya commences commercial operations in Australia with agreement with The Cardiac Centre NSW

Highlights

- **First commercial agreement in Australia with The Cardiac Centre NSW with a 12-month agreement for use of Artrya's Salix® Coronary Anatomy software for the diagnosis of cardiovascular disease**
- **Cardiovascular imaging specialists will use Salix to assess patients across four specialist cardiac centres in Wollongong, Shellharbour, Bowral and Nowra**
- **Successful progression from evaluating Salix Coronary Anatomy during a testing phase to commercial agreement with first revenues expected in Q4 FY24.**

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented AI platform that detects key coronary artery disease imaging markers, has entered its first commercial agreement ('Agreement') in Australia with The Cardiac Centre NSW and The Cardiac CT Centre NSW, based in the Illawarra and South Coast of New South Wales.

Under the 12-month Agreement, The Cardiac Centre NSW will use Artrya's Salix® Coronary Anatomy ('Salix') to detect vulnerable plaque in patients, the most accurate indicator of heart disease. Salix will be used across four specialist centres that comprise The Cardiac Centre NSW in Wollongong, Shellharbour, Bowral and Nowra. Collectively, these centres treat more than 25,000 patients per year for heart disease.

The AI-driven Salix platform will provide full diagnostic and evidence-based assessment within 10 minutes of first scan, dramatically improving the diagnosis workflow of coronary artery disease, saving unnecessary costs and minimising patient re-admissions. This Agreement follows a successful evaluation where Salix Coronary Anatomy was assessed and validated by cardiovascular imaging specialists in The Cardiac Centre NSW. First revenues are expected in Q4 FY24, with fees generated through a subscription model to the Salix platform.

Artrya CEO Mathew Regan said:

"Artrya delivers what we believe is the most advanced and seamless technology platform on the market for the detection, diagnosis, and care of coronary artery disease, creating a new standard of care for the number one cause of death in the world.

"I'm pleased to report that following a successful evaluation, The Cardiac Centre NSW has agreed to commercial terms for the use of Salix Coronary Anatomy across their specialist cardiac centres. We expect first revenues during Q4 FY24 following full integration of the Salix platform into their medical systems.

"This commercial agreement validates our strategy of entering new markets via evaluation periods, offering clinicians the opportunity to test and validate our technology, integrate it into their workflows, and experience firsthand the speed and accuracy of Salix in detecting heart disease compared to conventional methods.

Artrya Limited
ACN 624 005 741
1257 Hay Street West Perth WA 6005
PO Box 567 West Perth WA 6872
www.artrya.com
T: +61 8 6478 7816

“This agreement provides us access to four cardiac centres in NSW, a strong foundation to build on as we look to expand across NSW and other states in Australia.

“Heart disease is the leading cause of death in Australia, killing 155 Australians each day. Our AI-driven Salix Coronary Anatomy solution provides the first new approach to coronary heart diagnosis and care in 50 years. Salix provides full diagnostic and evidence-based assessment within 10 minutes of first scan, a game-changer in heart disease diagnosis, saving billions of unnecessary costs and minimising patient readmissions.”

The Cardiac CT Centre NSW’s senior cardiovascular imaging specialist, Dr Barry Ellison, said:

“We are thrilled to formally incorporate Salix as part of our first-line process to diagnose heart disease. Salix strengthens the comprehensive cardiac services we provide patients. This unique technology enables us to take a risk-based approach to patient care and personalised treatment by having a clear understanding of the different stages of plaque, and specifically the plaque that causes heart attacks.”

Dr Jorge Moragues, cardiologist and cardiac imaging specialist of The Cardiac CT Centre NSW added:

“One of the limitations of current standard diagnostic methods of ischaemic heart disease is the reliance on symptoms, as up to 50% of individuals who experience a heart attack may not have had any previous long-term or overt symptoms. Salix not only assists in identifying vulnerable plaque, an accurate indicator of disease; but significantly improves the diagnostic workflow of coronary artery disease.”

Material terms of the agreement

Material terms of the agreement are defined and listed in the attached Appendix 1.

This announcement was approved by the Board.

For further information please contact:

Investors

Danny Younis
+61 420 293 042
danny.younis@automicgroup.com.au

Media

Tristan Everett
+61 403 789 096
tristan.everett@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com.

Salix® is a trademark of Artrya Limited.

About The Cardiac Centre NSW

The Cardiac Centre NSW and The Cardiac CT Centre NSW provide a comprehensive range of cardiology services across four practices in Wollongong, Shellharbour, Bowral and Nowra. The group is the largest private cardiology practice in the Illawarra and South Coast of New South Wales and the only one with its own dedicated cardiac CT scanner.

Learn more at thecardiaccentre.com.au and cardiacctcentre.au.

Appendix 1

Key Terms

Licensee	The Cardiac Centre NSW
Contract type	SAAS Software Licence Agreement
Product	The Software as a Medical Device known as Salix® Coronary Anatomy.
Territory	Australia
Contract term	12-month subscription, renewable annually. Termination 30 days with written notice.
Revenue Impact	In this instance the revenue impact of this agreement is not considered material in value given the agreements short duration and size of the practice.
Special terms	Artrya will commence invoicing the Licensee upon completion of integration into Licensee's imaging and reporting systems. Licensee grants Artrya a licence to access, use, and retain in perpetuity anonymised scan data from Licensee's CCTA scan database.